Illumina

About Illumina

Illumina is a global leader in genomics, dedicated to unlocking the power of the genome to improve human health. Founded in 1998, the company has revolutionised the field of DNA sequencing and array-based technologies, making significant contributions to the understanding of genetic variation and its role in disease.

With a commitment to innovation, Illumina develops cutting-edge systems and solutions that enable researchers and clinicians to explore the complexities of the genome. Their comprehensive portfolio includes next-generation sequencing (NGS) platforms, genotyping arrays, and bioinformatics tools, all designed to facilitate genomic research and clinical applications.

Illumina’s vision is to enable the widespread adoption of genomics in healthcare, driving advancements in precision medicine. By providing accessible and affordable genomic information, they aim to empower healthcare professionals to make informed decisions that enhance patient outcomes.

The company operates globally, with a strong presence in the UK, where it collaborates with leading research institutions and healthcare providers. Illumina’s commitment to sustainability and ethical practices is evident in their efforts to reduce environmental impact and promote responsible use of genomic data.

• Core Activities:
• Development of next-generation sequencing technologies
• Genotyping and gene expression analysis
• Bioinformatics solutions for data interpretation

Illumina continues to push the boundaries of genomics, investing heavily in research and development to stay at the forefront of the industry. Their dedication to quality and customer satisfaction has established them as a trusted partner in the scientific community.

As the field of genomics evolves, Illumina remains committed to its mission of improving human health through innovative genomic solutions.